Literature DB >> 22709486

Measures in rheumatoid arthritis: are we measuring too many parameters.

S Chandrashekara1, S Sachin.   

Abstract

The disease activity measures in rheumatoid arthritis (RA) have a lot of unmet need for current clinical demand. With available biological and aggressive disease modifying anti-rheumatic drug therapy, the goal of RA treatment has moved toward remission or at least tighter control. The current measures lose their ability to discriminate further once the patient gets into minimal disease or tight control. There are more numbers of parameters, measured to assess disease activity, like joint counts, perception scales and laboratory parameters. There are different composite scores like Disease Activity Score, American College of Rheumatology criteria and clinical disease activity index. In this review we have reviewed the evolution of and changing need for these measures. The relevance of some measures and their use and limitations with reference to various characteristics are presented. Inflammation measures to quantify the RA process is the best way to monitor RA disease activity. C-reactive protein alone or with other biomarkers to specify RA, appear to be good prospective measures.
© 2012 The Authors International Journal of Rheumatic Diseases © 2012 Asia Pacific League of Associations for Rheumatology and Blackwell Publishing Asia Pty Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22709486     DOI: 10.1111/j.1756-185X.2012.01754.x

Source DB:  PubMed          Journal:  Int J Rheum Dis        ISSN: 1756-1841            Impact factor:   2.454


  7 in total

1.  Systemic inflammation response index (SIRI) as a novel biomarker in patients with rheumatoid arthritis: a multi-center retrospective study.

Authors:  Yunyun Xu; Hongjun He; Yinshan Zang; Zhe Yu; Huaixia Hu; Jiajia Cui; Wenwen Wang; Yingying Gao; Hua Wei; Zhuqing Wang
Journal:  Clin Rheumatol       Date:  2022-03-09       Impact factor: 2.980

2.  Identification of a specific haptoglobin C-terminal fragment in arthritic synovial fluid and its effect on interleukin-6 expression.

Authors:  Hyo Jung Park; Mi-Kyung Oh; Nam-Hoon Kim; Mi-La Cho; In-Sook Kim
Journal:  Immunology       Date:  2013-09       Impact factor: 7.397

Review 3.  C-reactive protein and the biology of disease.

Authors:  Waliza Ansar; Shyamasree Ghosh
Journal:  Immunol Res       Date:  2013-05       Impact factor: 2.829

4.  MeCP2-Related Diseases and Animal Models.

Authors:  Chinelo D Ezeonwuka; Mojgan Rastegar
Journal:  Diseases       Date:  2014-01-27

5.  Neutrophil-lymphocyte, platelet-lymphocyte and lymphocyte-monocyte ratios may not be useful markers to assess disease activity in rheumatoid arthritis: A STROBE-compliant article.

Authors:  Wang Lijuan; Zhou Yuting; Liang Chaoyang; Yang Ju
Journal:  Medicine (Baltimore)       Date:  2021-11-12       Impact factor: 1.817

6.  Low Serum BAFF Concentration Is Associated with Response to TNF Inhibitors in Seropositive Patients with Rheumatoid Arthritis.

Authors:  Borja Hernández-Breijo; Ioannis Parodis; Marta Novella-Navarro; Ana Martínez-Feito; Victoria Navarro-Compán; Mariana Díaz-Almirón; Dora Pascual-Salcedo; Alejandro Balsa; Chamaida Plasencia-Rodríguez
Journal:  J Clin Med       Date:  2022-09-02       Impact factor: 4.964

7.  A novel inflammatory biomarker, GlycA, associates with disease activity in rheumatoid arthritis and cardio-metabolic risk in BMI-matched controls.

Authors:  David B Bartlett; Margery A Connelly; Hiba AbouAssi; Lori A Bateman; K Noelle Tune; Janet L Huebner; Virginia B Kraus; Deborah A Winegar; James D Otvos; William E Kraus; Kim M Huffman
Journal:  Arthritis Res Ther       Date:  2016-04-12       Impact factor: 5.156

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.